2009 World Congress on the Insulin Resistance Syndrome: Cardiovascular Disease Concepts

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2010 Jul 1

PMID 20587709

Authors

Zachary T Bloomgarden

Affiliations

Soon will be listed here.

References

Balletshofer B, Rittig K, Enderle M, Volk A, Maerker E, Jacob S . Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation. 2000; 101(15):1780-4. DOI: 10.1161/01.cir.101.15.1780. View

Carter A, Cymbalista C, Spector T, Grant P . Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol. 2007; 27(12):2783-9. DOI: 10.1161/ATVBAHA.107.153221. View

Frye R, August P, Brooks M, Hardison R, Kelsey S, MacGregor J . A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009; 360(24):2503-15. PMC: 2863990. DOI: 10.1056/NEJMoa0805796. View

Caulfield M, Li S, Lee G, Blanche P, Salameh W, Benner W . Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin Chem. 2008; 54(8):1307-16. DOI: 10.1373/clinchem.2007.100586. View

Finfer S, Chittock D, Su S, Blair D, Foster D, Dhingra V . Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009; 360(13):1283-97. DOI: 10.1056/NEJMoa0810625. View

Wiviott S, Braunwald E, Angiolillo D, Meisel S, Dalby A, Verheugt F . Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in.... Circulation. 2008; 118(16):1626-36. DOI: 10.1161/CIRCULATIONAHA.108.791061. View

Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R . Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678):1849-60. PMC: 2715005. DOI: 10.1016/S0140-6736(09)60503-1. View

Musunuru K, Orho-Melander M, Caulfield M, Li S, Salameh W, Reitz R . Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol. 2009; 29(11):1975-80. PMC: 2772123. DOI: 10.1161/ATVBAHA.109.190405. View

Cubbon R, Gale C, Rajwani A, Abbas A, Morrell C, Das R . Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. Diabetes Care. 2007; 31(2):363-5. DOI: 10.2337/dc07-1745. View

10.

Derian C, Damiano B, Addo M, Darrow A, DAndrea M, Nedelman M . Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther. 2003; 304(2):855-61. DOI: 10.1124/jpet.102.042663. View

11.

Svensson A, McGuire D, Abrahamsson P, Dellborg M . Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005; 26(13):1255-61. DOI: 10.1093/eurheartj/ehi230. View

12.

Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427-43. DOI: 10.1056/NEJMoa066224. View

13.

Jaap A, Hammersley M, Shore A, Tooke J . Reduced microvascular hyperaemia in subjects at risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1994; 37(2):214-6. DOI: 10.1007/s001250050096. View

14.

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

15.

Dormandy J, Charbonnel B, Eckland D, Erdmann E, Massi-Benedetti M, Moules I . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493):1279-89. DOI: 10.1016/S0140-6736(05)67528-9. View

16.

Ginsberg H, Elam M, Lovato L, Crouse 3rd J, Leiter L, Linz P . Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1563-74. PMC: 2879499. DOI: 10.1056/NEJMoa1001282. View

17.

Donahoe S, Stewart G, McCabe C, Mohanavelu S, Murphy S, Cannon C . Diabetes and mortality following acute coronary syndromes. JAMA. 2007; 298(7):765-75. DOI: 10.1001/jama.298.7.765. View

18.

Welin L, Wilhelmsen L, Bjornberg A, Oden A . Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study. Pharmacoepidemiol Drug Saf. 2009; 18(12):1143-9. DOI: 10.1002/pds.1828. View

19.

St-Pierre A, Cantin B, Dagenais G, Mauriege P, Bernard P, Despres J . Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2004; 25(3):553-9. DOI: 10.1161/01.ATV.0000154144.73236.f4. View

20.

Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M . Intensive insulin therapy in critically ill patients. N Engl J Med. 2002; 345(19):1359-67. DOI: 10.1056/NEJMoa011300. View